Showing results (1-10 of 155) with videos related to
Sort By:
Pageof 16
Leukemia & Lymphoma|September 20, 2019
Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative diseasePiers BlomberyJournal of Blood Medicine|February 14, 2014
Management of thrombotic thrombocytopenic purpura: current perspectivesPiers Blombery, Marie ScullyBlood|January 14, 2025
Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitorsConstantine S Tam, Shalini Balendran, Piers BlomberyMethods in Molecular Biology (Clifton, N.J.)|December 3, 2016
Recurrent Cytogenetic Abnormalities in Myelodysplastic SyndromesMeaghan WallHematology/Oncology Clinics of North America|November 28, 2016
Transformed LymphomaMary Ann Anderson, Piers Blombery, John F SeymourPlastic and Reconstructive Surgery|March 1, 2019
Molecular Drivers of Breast Implant-Associated Anaplastic Large Cell LymphomaPiers Blombery, Ella R Thompson, H Miles PrinceCurrent Treatment Options in Oncology|May 30, 2023
Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell LymphomaSimon Wu, Piers Blombery, David Westerman, et al.Blood Advances|January 15, 2020
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 monthsThomas E Lew, Mary Ann Anderson, Victor S Lin, et al.Haematologica|December 15, 2018
Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemiaMelita Kenealy, Mark Hertzberg, Warwick Benson, et al.International Journal of Laboratory Hematology|March 6, 2020
Diagnostic evaluation and considerations in hypocellular bone marrow failure-A focus on genomicsLucy C Fox, Erica M Wood, David S Ritchie, et al.Pageof 16